Daily Judi: Friday, December 23, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Elise Reuter speaks with CEO Mike Nolan, of Freenome, a biotech company that has created a blood-based test targeting colon cancer. Freenome's colorectal cancer test is now engaged in a 40,000-person clinical trial. (MedTech Dive)
Abigail Dirks, Kenneth Getz, Robert Howie, and Mary Jo Lamberti, Ph.D., examine of the role of the Clinical Research Associate in the face of workforce challenges resulting from the COVID-19 pandemic. (Applied Clinical Trials)
Selin Kurnaz, CEO of Massive Bio, which connects cancer patients to clinical trials using AI, discusses re-engineering clinical trials. She writes, "Adopting an engineering mindset in oncology research can fix all the broken constituent processes like patient enrollment to systematize clinical trials." (MedCity News)
For over a decade, Janssen Pharmaceuticals has hosted an art collection, featuring the work of advocates, patients, caregivers, and Janssen's scientists.
Our Culture
“The Judi platform is purpose-built to drive clinical trial success—cloud-based, secure, collaborative. Our greatest strength, above all else, is our people."
–Abraham Gutman, President & CEO
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
